Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC

Nov 7, 20244 min read

Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors

May 21, 20242 min read

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Mar 5, 20242 min read

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Feb 15, 20242 min read

Dragonfly Initiates Phase 1/1b Study of its IL-2 Immunotherapy

Dec 5, 20232 min read

One R.I. man’s battle with Stage 4 colon cancer

Aug 8, 20235 min read

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

Jun 5, 20234 min read

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Apr 16, 20232 min read

Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine

Feb 5, 20232 min read

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Jan 6, 20232 min read

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dec 8, 20222 min read

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

Dec 5, 20222 min read

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Nov 1, 20222 min read

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop NK Cell Engagers

May 1, 20221 min read

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Apr 20, 20222 min read

Dragonfly Therapeutics Expands Clinical Leadership Team

Mar 30, 20222 min read

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Mar 1, 20221 min read

Merck and Dragonfly, Together Again

Nov 24, 20212 min read

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

Nov 24, 20211 min read

Merck hits 'go' on a second Dragonfly drug

Nov 24, 20211 min read